Surufatinib

Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.^[1]

Surufatinib

Clinical data
Trade names	Sulanda
Other names	Sulfatinib; HMPL-012
ATC code	L01EX24 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-[2-(Dimethylamino)ethyl]-1-[3-{{#parsoidfragment:2}}4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
CAS Number	1308672-74-3
PubChem CID	52920501
IUPHAR/BPS	9769
DrugBank	DB15106
ChemSpider	57583328
UNII	B2K5L1L8S9
ChEMBL	ChEMBL4297190
Chemical and physical data
Formula	C24H28N6O3S
Molar mass	480.59 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
InChI InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29) Key:TTZSNFLLYPYKIL-UHFFFAOYSA-N

It is also under investigation for the treatment of other types of solid tumors.^[2][3]

Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).^[4]